CAJ | 학술논문

目的：发现并探讨新型抗 HER3/ EGFR 双特异性抗体 NB031在口腔鳞状细胞癌(OSCC)中的靶向治疗作用。方法筛选与鉴定双特异性抗体 NB031；MTT 法检测 NB031对 OSCC 细胞增殖的影响；Western Blotting 法检测NB031对下游信号通路的影响；通过建立裸鼠 KB OSCC 模型,比较生理盐水、cetuximab 和 NB031对肿瘤体积的影响。结果 Cetuximab 和 NB031均降低 HSC3和 KB 细胞增殖能力,NB031抑制效果明显大于 cetuximab；与 cetuximab 相比, NB031显著降低 EGFR 和 HER3及它们下游信号的磷酸化；cetuximab 和 NB031均降低肿瘤体积增长速率,NB031作用更明显。结论相比 cetuximab,NB031能够更有效地抑制人 OSCC 细胞生长,是一种具有潜在前景的靶向治疗制剂。
목적：발현병탐토신형항 HER3/ EGFR 쌍특이성항체 NB031재구강린상세포암(OSCC)중적파향치료작용。방법사선여감정쌍특이성항체 NB031；MTT 법검측 NB031대 OSCC 세포증식적영향；Western Blotting 법검측NB031대하유신호통로적영향；통과건립라서 KB OSCC 모형,비교생리염수、cetuximab 화 NB031대종류체적적영향。결과 Cetuximab 화 NB031균강저 HSC3화 KB 세포증식능력,NB031억제효과명현대우 cetuximab；여 cetuximab 상비, NB031현저강저 EGFR 화 HER3급타문하유신호적린산화；cetuximab 화 NB031균강저종류체적증장속솔,NB031작용경명현。결론상비 cetuximab,NB031능구경유효지억제인 OSCC 세포생장,시일충구유잠재전경적파향치료제제。
Objective To find and explore effect of a new bispecific antibody NB031 targeted both epidermal growth factor receptor (EGFR) and HER3 signaling in targeted therapy of oral squamous cell carcinoma (OSCC). Meth-ods A bispecific antibody NB031 was screened and identified; MTT assay was performed to investigate the influence of NB031 on OSCC cell multiplication; the influence of NB031 on down-streamed signal pathway was identified using West-ern blot analysis; the effects of normal saline, Cetuximab and NB031 on tumor volumes were compared by establishing Xenotransplanted nude mouse tumorigenesis models of OSCC. Results Both Cetuximab and NB031 could inhibit cells proliferation of HSC3 and KB, and NB031 was more effective in inhibition than that by Cetuximab; compared with those by Cetuximab, NB031 significantly suppressed phosphorylation levels of EGFR, HER3 and both down-streamed signal;growth rate of tumor volume was decreased by both Cetuximab and NB031, and the inhibition effect of NB031 was more obvious than that of Cetuximab. Conclusion Compared with those by Cetuximab, NB031 may more effectively inhibit human OSCC cell growth, and it can be used as a potential prospect of agent for targeted therapy.